Our focus around the media and technology sectors and understanding of IP rich businesses, coupled with our fully integrated European patent attorney practice, is unique amongst UK law firms.

Our venture capital group integrates commercial and intellectual property practitioners who are able to bring the benefit of their knowledge and expertise acting for some of the leading businesses in various technology sub-sectors to clients investing or seeking venture capital funding, whether it be via due diligence, initial set up of the venture or key business contracts.

We act for companies looking for venture capital funding and well known VC investors in the UK, US and mainland Europe looking to make venture investments whether it be mainstream technology companies or life sciences and healthcare related opportunities.

Advised StrikeAd, the London and New York based mobile advertising specialists, on its £2 million second round investment from venture capital firm DFJ Esprit.

Advised the founder shareholders of Autifony Therapeutics Limited ("ATL") and ATL, a newly-established biotechnology company, in relation to the acquisition of certain clinical assets from GlaxoSmithKline; the Series A fundraising carried out by ATL raising £10.4 million from a syndicate of leading life science investors; and the related shareholder arrangements between the founder shareholders, GlaxoSmithKline and the new institutional investors. 

Advised MVM Life Science Partners LLP, Abingworth LLP and their respective investment funds, venture capital investors in the life sciences industry, on their £13 million subscription for shares in Lombard Medical Technologies Limited (Lombard), the AIM quoted medical technology developer as part of a secondary fundraising by Lombard through which it sought to raise a total of up to £27.5 million.

Advised the founder shareholders of Convergence Pharmaceuticals Limited ("CPL") and CPL, a newly-established biotechnology company, in relation to the acquisition of certain clinical assets from GlaxoSmithKline; the Series A fundraising carried out by CPL raising $35.4 million from a syndicate of leading European and US life science investors; and the related shareholder arrangements between the founder shareholders, GlaxoSmithKline and the new institutional investors.

Advised Kymab Limited, a biotechnology company developing a state-of-the-art next generation human monoclonal antibody platform, on its Series A venture capital investment of up to £20 million by The Wellcome Trust.

Advised app developer Zeebox on the sale of a 10% equity stake to British Sky Broadcasting as part of its investment in the growing 'dual screen' trend.